Medrobotics said it closed on $20 million in new funding in a preferred stock sale to prior backers as plans to expand its commercial footprint in Europe.

Raynham, Mass.-based Medrobotics also said that it’s "met all applicable FDA requirements" to distribute its Flex Retractor in the U.S.

"The new investment from our shareholders enables the company to continue its operations well into the future while it commercializes first in Europe and then, upon clearance, in other parts of the world," CEO Samuel Straface said in prepared remarks.

The company, which won CE Mark approval in the European Union to sell its Flex system and retractor in Europe last March, raised a $26 million Series E round in May.

In July the company announced the German market release of the Flex device.